Recent Transactions

27-Sep-23
Undisclosed
United States flag
Target: 

Slayback Pharma LLC

United States flag
Acquiror: 
Azurity Pharmaceuticals

Advised Azurity Pharmaceuticals, a pharmaceutical company specializing in the provision of innovative medicines to overlooked patients, on the acquisition of Slayback Pharma LLC ("Slayback"), a company focused on complex generic and specialty pharmaceutical products

30-Dec-22
$153 million
United States flag
Target: 

Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products

Australia flag
Acquiror: 
Mayne Pharma

Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma

19-Aug-22
$2.2 billion
United States flag
Target: 

GI Alliance

United States flag
Acquiror: 
Apollo Hybrid Value Fund

Advising the management and majority physician owners of GI Alliance, the largest gastroenterology practice in the United States, on its recapitalization and buyout of minority partner, Waud Capital

19-Feb-21
$33 million
U.S.A., U.K. flags
Target: 

Acacia Pharma Group plc

flag not available
Acquiror: 
N/A

Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share

09-Feb-21
Undisclosed
United States flag
Target: 

US Acute Care Solutions

United States flag
Acquiror: 
Apollo Hybrid Value Fund

Advising US Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on its recapitalization and buyout of minority partner, Welsh Carson

01-Oct-20
$1.05 billion
United States flag
Target: 

Akorn, Inc.

flag not available
Acquiror: 
First Lien Term Loan Lenders

Advised Ad Hoc Group of First Lien Term Loan Lenders on Akorn’s in-court recapitalization

12-Nov-18
$84 million
Australia flag
Target: 

AUB Group Limited

flag not available

Advised ASX-listed AUB Group, a leading insurance intermediary business operating a network of over 100 insurance brokers and underwriting agencies across Australia and New Zealand, on its fully underwritten entitlement offer to raise A$116mm

28-Sep-18
$NA
Australia flag
Target: 

Blue Sky Alternative Investments Limited

United States flag
Acquiror: 
Oaktree Capital Management L.P.

Advised Blue Sky, an ASX-listed diversified alternative assets manager, on its response to an activist short-seller campaign, strategic review of recapitalisation options, and receipt of a A$50mm long-term capital investment by Oaktree via a 7-year senior secured convertible loan note facility

02-May-18
$3.7 billion
Canada flag
Target: 

Concordia International Corp.

flag not available

Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt

04-Oct-16
$223 million
U.S.A., U.K. flags
Target: 

US rights to Toprol-XL (AstraZeneca)

Canada flag
Acquiror: 
Aralez Pharmaceuticals Inc.

Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.

09-Aug-16
$NA
Australia flag
Target: 

Bionomics Limited

flag not available

Advised ASX-listed Bionomics, a clinical stage biopharmaceutical company focused on the treatment of serious central nervous system disorders and cancer, on a consultation process with shareholders following calls for Board change, leading to the formation of a shareholder working group of leading institutional investors and company-led Board renewal.

21-Apr-15
$963 million
flag not available
Target: 

Refinancing of syndicated bank debt facilities

Australia flag
Acquiror: 
Primary Health Care

Advised Primary Health Care on the refinancing of its A$1.25 billion syndicated bank debt facilities

12-Jun-13
$893 million
Australia flag
Target: 

A$1.6bn non-core loan portfolio

United States flag
Acquiror: 
Goldman Sachs Group. Inc.

Advised Suncorp Group Ltd (ASX:SUN), a leading general insurance, retail banking and life insurance group in Australia and New Zealand, on the sale of a A$1.6bn portfolio of performing and non-performing (corporate and property) loans to Goldman Sachs Group Inc., an American multinational investment banking firm

11-Dec-12
$51.6 billion
United States flag
Target: 

American International Group (AIG)

Advised the United States Department of the Treasury (“UST”) on the full reduction of its 92% ownership stake in the insurer through numerous Secondary Public Offering Transactions

27-Sep-12
$1.5 billion
United States flag
Target: 

The Hartford’s Individual Life Insurance Business

United States flag
Acquiror: 
Prudential Financial, Inc.

Advised The Hartford, a leading provider of insurance and wealth management services, on the divestiture of its Individual Life Insurance Business to Prudential Financial, Inc.

04-Sep-12
$600 million
United States flag
Target: 

The Hartford’s Retirement Plans Group

United States flag
Acquiror: 
Massachusetts Mutual Life Insurance Company

Advised The Hartford, a leading provider of insurance and wealth management services, on the divestiture of its Retirement Plans Group to Massachusetts Mutual Life Insurance Company, a leading mutual life insurance company

16-Dec-11
$NA
United States flag
Target: 

ISTA Pharmaceuticals, Inc.

Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its defense against an unsolicited offer from Valeant Pharmaceuticals and on its review of strategic alternatives

13-May-11
$NA
Australia flag
Target: 

Bionomics Ltd

Advised Bionomics Ltd, in relation to the tender process run by Bionomics’ largest shareholder, Start-up Australia Ventures (“Start-up”), for its 28% stake in the company, follow on sell-down of Start-up’s stake to 8% and associated capital raising by Bionomics

01-Mar-11
$122 million
Australia flag
Target: 

Australian Unity Limited

Advised Australian Unity Limited, a leading healthcare, financial services and retirement living mutual organisation, on its A$120 million issue of five year unsecured notes listed on the Australian Stock Exchange

07-Feb-11
$548 million
United States flag
Target: 

Wesco Financial Corporation

United States flag
Acquiror: 
Berkshire Hathaway Inc.

Advised the Special Committee of Wesco Financial Corporation in connection with Berkshire Hathaway Inc.'s proposal to acquire the remaining 19.9% of the shares of Wesco’s common stock that it does not presently own

15-Dec-10
$12.9 billion
U.S.A., Swiss flags
Target: 

Alcon, Inc.

Switzerland flag
Acquiror: 
Novartis AG

Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company

22-Nov-10
$NA
United States flag
Target: 

US Department of the Treasury

Advised the United States Department of the Treasury on the management and disposition of its common shares of AIG

28-Jun-10
$1.3 billion
U.K., Australia flags
Target: 

Guinness Peat Group plc

Advised GPG plc, a listed investment company, on potential restructuring alternatives

07-Mar-08
$1.5 billion
United States flag
Target: 

Ambac Financial Group, Inc.

Advised a consortium of leading global financial institutions and investors, including but not limited to Banc of America Securities LLC; Citigroup Global Markets Inc.; Dresdner Kleinwort Securities LLC; Keefe, Bruyette & Woods, Inc.; and UBS Securities LLC, on its participation in a recapitalization of Ambac Financial Group, Inc.

30-May-07
$5.3 billion
United States flag
Target: 

Ceridian Corporation

United States flag
Acquiror: 
Thomas H. Lee Partners and Fidelity National Financial

Acted as sole financial adviser to Ceridian Corporation, an information services provider to the human resource, transportation and retail markets, on its sale to Thomas H. Lee Partners and Fidelity National Financial

Pages

show all